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Abstract  
RFamide peptides 43RFa and 26RFa have been shown to promote food intake and to exert different 
peripheral actions through GPR103 receptor binding. Moreover, 26RFa was found to inhibit 
pancreatic insulin secretion, whereas the role of 43RFa on β-cell function is unknown, as well as the 
effects of both peptides on β-cell survival. Herein, we investigated the effects of 43RFa and 26RFa 
on survival and apoptosis of pancreatic β-cells and human pancreatic islets. In addition, we  
explored the role of these peptides on insulin secretion and the underlying signaling mechanisms. 
Our results show that in INS-1E β-cells and human pancreatic islets, both 43RFa and 26RFa 
prevented cell death and apoptosis induced by serum starvation, cytokine synergism and 
glucolipotoxicity, through PI3K/Akt- and ERK1/2-mediated signaling. Moreover, 43RFa promoted, 
whereas 26RFa inhibited glucose- and exendin-4-induced insulin secretion, through Gαs and Gαi/o 
proteins, respectively. Inhibition of GPR103 expression by small interfering RNA blocked 43RFa 
insulinotropic effect, but not the insulinostatic action of 26RFa. Finally, 43RFa, but not 26RFa, 
induced cAMP increase and glucose uptake. In conclusion, because of their survival effects along 
with the effects on insulin secretion, these findings suggest potential for 43RFa and 26RFa as 
therapeutic targets in the treatment of diabetes. 
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Pancreatic beta cell mass plays an essential role in glucose homeostasis. The reduced capacity of the 
endocrine pancreas to maintain an adequate insulin secretion, due to decreased β-cell mass and 
function, underlies both type 1 and type 2 diabetes (1). In type 1 diabetes, immune-mediated release 
of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) 
and interleukin-1β (IL-1β) has been implicated in β-cell apoptosis (2). In type 2 diabetes, β-cell 
apoptosis results from the combined action of increased plasma glucose/free fatty acid levels 
(glucolipotoxicity) (3) and cytokines (4). Therefore, identifying molecules capable of increasing 
pancreatic β-cell survival may be crucial for the treatment and prevention of diabetes. 
RFamide-related peptides constitute a family of biologically active peptides terminating in arginine-
phenylalanine-amide (Arg-Phe-NH2) at their C-terminus. They include a 26-aminoacid RFamide 
peptide (26RFa), that was isolated from the frog brain (5), and a longer form of 26RFa, a 43-
aminoacid peptide with a pyroglutamylated RFamide (termed QRFP-43 or 43RFa). Both peptides 
were identified as the cognate ligands of the orphan G protein-coupled receptor 103 (GPR103) 
(6,7). In humans and rodents, 43RFa, 26RFa and GPR103 are mainly expressed in brain, 
particularly in the hypothalamus (8), as well as in peripheral tissues, including the eye, testis, 
thyroid, adipose tissue and macrophages (6,9-11). 43RFa and 26RFa have been implicated in many 
physiological functions, including stimulation of food intake (5,12-17), regulation of gonadotropic 
axis (18,19), aldosterone secretion (7,20), bone formation (21), adipogenesis and inflammation 
(10,11), blood pressure (12) and prostate cancer differentiation and migration (22).  
Recently, 26RFa has been shown to regulate peripheral glucose metabolism through inhibition of 
glucose-induced insulin secretion in the perfused rat pancreas, without affecting glucagon secretion. 
This effect involved inhibition of the adenylyl cyclase/cAMP system via a pertussin toxin (PTX)-
sensitive Gi protein (23). On the other hand, to our knowledge, the role of 43RFa on insulin 
secretion is unknown, as well as the effect of both peptides on pancreatic β-cell survival. Therefore, 
in the present study we sought to determine the role of both 43RFa and 26RFa on survival and 
apoptosis of pancreatic β-cells and human pancreatic islets, particularly in stress conditions such as 
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serum starvation, cytokine synergism or glucolipotoxicity. Furthermore, we investigated the effects 
of the peptides on insulin secretion and the underlying signaling mechanisms.  
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Research Design and Methods 
Reagents 
Rat QRFP-43 (43RFa), QRFP-26 (26RFa) and Exendin-4 were from Phoenix Pharmaceuticals 
(Karlsruhe, Germany). PD-98059, Wortmannin, PTX, NF449, Hoechst-33258, 3-isobutyl-1-
methylxanthine (IBMX), MTT, forskolin, glucose, palmitate, Mammalian cell lysis kit were from 
Sigma-Aldrich (Milano, Italy). Cytokines (TNF-α, INF-γ and IL-1β) were from Life Technologies, 
Milan Italy. [
3
H]-2-deoxi-D-glucose was from Perkin Elmer Life Sciences Inc. (Boston, MA). Cell 
culture and RT-PCR reagents were from Life Technologies (Milan, Italy). P-Akt (Ser473), P-
ERK1/2, ERK1/2 and Akt antibodies were from Cell Signaling Technology (Euroclone, Milan, 
Italy), β-actin  antibody was from Santa Cruz (D.B.A. Italia, Milan, Italy). GPR103-antibody was 
from Abcam (Prodotti Gianni, Italy) and QRFP from Phoenix Pharmaceuticals (Burlingame, CA), 
for either immunohistochemistry, immunofluorescence and Western blot experiments. Primers for 
RT-PCR were from from IDT (Tema Ricerca, Bologna, Italy).  
 
Cell culture 
INS-1E rat β-cells were kindly provided by Prof. Claes B. Wollheim (Department of Cell 
Physiology and Metabolism, University of Geneva, Geneva, Switzerland) and cultured as described 
(24). 
 
Human islet isolation  
Human islets were obtained from pancreases of multiorgan donors as described (24). Islet 
preparations with purity >70%, not suitable for transplantation, were used after approval by the 
local ethical committee. Islets (10,000) were cultured in CMRL (Invitrogen) with 10% FBS. 
 
RT-PCR and Real Time PCR 
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Total RNA extraction and reversed transcription to cDNA from 3 µg RNA was performed as 
described (24). The following primer sequences were used: rat/mouse/human GPR103, Fwd: 5’-
TAGGATCACCCATGTGGCACGT-3’, Rev: 5’-AAGAGAGCCACCACTGTCACCATC-3’ 
[AB109629.1] (21); human QRFP, Fwd 5’-ATGGTAAGGCCTTACCCCCTGATCTAC-3’, Rev 
5’-CCTGTGGCTGTGAAGCTCT-3’ (BC101127.2); rat QRFP, Fwd 5’-
AGCACACTGGCTTCCGTCTAG-3’, Rev 5’-CGCTGGCCTTCTCTGAGTCA-3’ (NM198200.1) 
(7); 18S rRNA, Fwd: 5’-GTGGAGCGATTTGTCTGGTT-3’, Rev: 5’-
CGCTGAGCCAGTTCAGTGTA-3’ (X_01117). 9 µl cDNA were amplified (GeneAmp PCR 
System, Perkin Elmer, Milan, Italy) in 50 µl under the following conditions: 94°C for 30 sec, 60°C 
for 30 sec annealing; 72°C for 60 sec, 72°C for 7 min. The final PCR products (318 bp for GPR103, 
196 bp for human QRFP, 300 bp for rat QRFP, 199 bp for 18s rRNA) were separated by 1.5% 
agarose gel electrophoresis and visualized by ethidium bromide staining.  
 
GPR103 immunofluorescence  
INS-1E β-cells and human pancreatic islets were seeded on glass coverslips in complete medium 
for 2 days, then washed twice with PBS. INS-1E cells were allowed to grow up to 50-60% 
confluence. The cells were then fixed with 4% paraformaldehyde and incubated with goat anti-
GPR103 antibody overnight at 4°C. After washing  three times with PBS, cells were incubated with 
anti-goat secondary TRITC-conjugated antibody (Life Technologies, Milan, Italy) for 1 h at room 
temperature. Nuclei were stained with 4'-6-diamidino-2-phenylindole (DAPI). Red and blue 
channels were assigned to GPR103 and nuclei, respectively. Images were taken using a Leica 
DM200 fluorescent microscope and a Leica DFC340 FX camera. Adult rat hippocampal (AHP) 
cells were used as positive control. 
 
Immunohistochemistry 
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Human pancreatic tissue (n=3 samples) was obtained from surgical samples of non-pancreatic 
diseases; pituitary samples (n=3 samples) were obtained from autopsies. Tissues were fixed in 
buffered formalin and embedded in paraffin. Five-µm-thick sections were de-paraffinized and re-
hydrated in graded alcohols and phosphate-buffer pH 7.5, and endogenous peroxidase activity was 
blocked by absolute methanol and 0.3% hydrogen peroxide for 15 min. To assess the presence of 
GPR103 and QRFP proteins, the following primary antibodies and conditions were employed: 
rabbit polyclonal antibody to GPR103 (Abcam, Cambridge, UK; diluted 1:150) and rabbit 
polyclonal antibody to QRFP-43 (Phoenix Pharmaceuticals, Burlingame CA, USA; diluted 1:150). 
Immunoreactions were revealed by a dextran-chain (biotin-free) detection system (EnVision; 
Dako), using 3,3-diaminobenzidine (DAB; Dako) as a chromogen. 
 
Cell proliferation and survival 
Cell proliferation was assessed by BrdU incorporation ELISA (Roche), as previously described 
(25). Cells were seeded on 96-well plates at 5x10
3
 cells/well in serum-containing medium until 60–
70% confluence and serum-starved for 24 h before treatments. Cell survival was assessed by MTT 
as previously described (25). 
 
Hoechst staining 
Morphological changes in the nuclear chromatin of apoptotic cells were detected by Hoechst 33258 
staining as previously described (24). 500 stained nuclei were double counted under a fluorescence 
microscope (DAPI filter).  
 
Caspase 3 activity 
Caspase 3 activity was assessed by Caspase-3 Colorimetric Kit (Assay Designs, Italy) in INS-1E β-
cells and human islet cell lysates, according to the manufacturer’s instruction.  
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cAMP assay 
Starved 8X10
5 
INS-1E β-cells and 1X10
3 
human islets were seeded in 100-mm dishes. After 
incubations, in the presence of IBMX (100 µmol/l), cAMP was measured from lysates, using the 
Direct Cyclic AMP EIA kit (Assay Designs, Italy) according to the manufacturer’s instructions. 
Forskolin was used as positive control. 
 
Western blotting 
40 µg proteins for P-ERK and P-Akt, and 60 µg for GPR103 and QRFP were resolved in 12% SDS-
PAGE. Proteins were treated as described (24) and incubated with the specific antibody (dilution 
1:1000). Blots were reprobed with the respective total antibodies or with β-actin for normalization. 
Immunoreactive proteins were visualized with Chemidoc XRS (Bio-Rad, Milan Italy), and 
densitometric analysis was performed with Quantity One software (Bio-Rad). 
 
Insulin secretion 
Insulin secretion in INS-1E β-cells was performed as described (24). Human pancreatic islets (n=3) 
were incubated for 1 h at 37 C in HEPES-buffered Krebs-Ringer bicarbonate buffer containing 
0.5% BSA with 2 mmol/L glucose. The medium was changed, and the cells were incubated again 
for 1 h in Krebs-Ringer bicarbonate buffer/0.5% BSA containing 1.25, 7.5, 15 or 25 mmol/L 
glucose, with or without the different peptides or inhibitors. After acid ethanol extraction of the 
hormone, secreted insulin was quantified by a RIA kit (Linco Research, Labodia, Yens, 
Switzerland) that recognizes human insulin and cross-reacts with rat insulin. 
 
Small interfering RNA (siRNA) 
Rat Qrfpr Silencer Select Pre-designed siRNA (s160302) (GPR103 siRNA), Silencer Negative 
Control siRNA #1 (cat AM4611) and Lipofectamine RNAiMAX were purchased from Life 
Technologies (Monza, Italy). INS-1E cells (2 d post seeding) were transfected in RPMI-1640 serum 
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free medium (Sigma-Aldrich) without antibiotics, with 50 nmol/L Control or GPR103 siRNAs 
using Lipofectamine RNAiMAX, according to the manufacturer's instructions. After 24 h the cells 
were used for insulin measurement experiments. Efficiency of transfection was assessed by RT-
PCR. 
 
[
3
H]-2-deoxyglucose uptake  
[3H]-2-deoxyglucose uptake was performed in both INS-1E β-cells and human pancreatic islets. 
Pancreatic islets were dissociated with StemProAccutase (Gibco, Invitrogen, San Diego, CA, USA) 
(25). β-cells were incubated in Hepes buffer without glucose, with either Ex-4, 43RFa or 26RFa for 
20 min, and then with 6 mmol/L 2-deoxyglucose and 1 Ci/mL [
3
H]-2-deoxyglucose for 5 or 10 min, 
without Hepes buffer removal. Human islets were incubated in serum-free medium with the 
peptides for 20 min, then the media was aspirated and Hepes buffer containing 20 mmol/L 2-
deoxyglucose and 1 Ci/mL [
3
H]-2-deoxyglucose was added for 10 min. The reaction was stopped 
by washing 3 times with ice cold PBS. Cells were solubilized on ice with lysis buffer (NaOH 50 
mmol/L). Equal amounts of lysates were mixed with scintillation fluid, and specific activity was 
counted in a liquid scintillation counter (Beckman Instruments, Fullerton, CA) in duplicate. [
3
H]-2-
deoxyglucose uptake, expressed as pmol//mg, was normalized by using a BCA protein 
quantification of each sample, as described (26). 
 
Statistical analysis 
Results are presented as means ± SE. Results were analyzed using 2-tailed Student’s t test or two-
way ANOVA followed by Tukey’s HSD for post-ANOVA comparisons (GraphPad Prism 5.0 
software, San Diego, CA). Significance was established when P<0.05. 
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Results 
GPR103 and QRFP are expressed in INS1-E β-cells and human pancreatic islets 
RT-PCR analysis showed mRNA expression of both GPR103 and QRFP, the precursor of RF43a 
and 26RFa, in pancreatic INS1-E β-cells and human pancreatic islets (Figure 1A and B). At the 
protein level, Western blot analysis showed presence of both GPR103 and QRFP, the precursor 
peptide of RF43a and 26RFa, in INS-1E β-cells and human pancreatic islets (Figure 1 C and D). 
Furthermore, immunofluorescence analysis revealed GPR103 protein expression in both β-cells 
(Figure 1E) and human islets, where GPR103 showed partial colocalization with insulin in β-cells 
(Figure 1F). Immunohistochemical studies also confirmed expression of both GPR103 and QRFP, 
in INS1-E β-cells and human pancreatic islets (Figure 1G and H). In human pancreas, GPR103 
positivity was found in endocrine pancreatic cells, being negative in acinar cells. Similarly, QRFP 
was positive in pancreatic islets and negative in acinar cells (Figure 1H). Pituitary was used as 
positive control, showing strong staining for GPR103 in the posterior lobe (neurohypophysis) but 
almost negative staining in the anterior lobe (adenohypophysis) (Figure 1H). QRFP was negative in 
the neurohypophysis and weakly positive in isolated cell clusters of the adenohypophysis 
(corresponding to acydophilic cells) (Figure 1H). 
  
43RFa and 26RFa both promote survival and proliferation and inhibit apoptosis in INS1-E β-
cells  
One of the major pathological conditions, responsible for the progression of diabetes, is β-cell loss 
by apoptosis and decreased β-cell mass. Therefore, we tested the hypothesis as to whether 43RFa 
and 26RFa may protect β-cells and human pancreatic islets from the harmful effects of stimuli 
classically involved in diabetes, such as cytokines or glucolipotoxicity.  
43RFa and 26RFa effects on survival and proliferation were assessed in INS1-E β-cells cultured in 
serum-free medium, in either absence or presence of the inflammatory cytokines interferon-gamma 
(IFN-γ), tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). Serum starvation per 
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se is known to reduce survival in many cell types and cytokine synergism has been implicated in β-
cell destruction and apoptosis in both type 1 and type 2 diabetes (4,25). 43RFa and 26RFa were 
initially tested at different concentrations (1, 10, 25, 50 and 100 nmol/L). Both peptides increased 
cell survival under serum starvation from 10 to 100 nmol/L, as assessed by MTT assay (Figure 2A). 
In cytokine-treated cells, they both promoted survival at all the concentrations tested, showing the 
greatest effect  at 100 nmol/L (Figure 2B). Similar results were obtained by performing the Trypan 
blue assay (data not shown). 43RFa and 26RFa also increased cell proliferation under serum 
starvation at all the concentrations tested (Figure 2C), whereas with cytokines, they were effective 
from 25 to 100 nmol/L (Figure 2D). As for cell survival, the best proliferative effect was observed 
at 100 nmol/L, for both peptides, with a slight dose-response under cytokine treatment. Notably, 
under either serum starvation or cytokines, at 100 nmol/L the peptides increased survival and 
proliferation up to levels comparable to those of serum and serum-free medium, respectively.  
The glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 (Ex-4), which exerts 
antiapoptotic, survival and proliferative effects in β-cells (27), was used as control peptide. The 
survival and proliferative effects of Ex-4 were comparable to those of 43RFa and 26RFa, 
particularly at 100 nmol/L (Figure 2A-D). 
Glucolipotoxicity, caused by excessive glucose and/or lipids, is a consequence of type 2 diabetes 
and a major cause of β-cell dysfunction and death (3). Based on the results obtained in cytokine-
treated cells, 43RFa and 26RFa, were tested at 100 nmol/L, the concentration that was chosen for 
the following experiments. The peptides equally increased INS-1E β-cell survival and proliferation, 
that were both reduced in cells incubated with high glucose (30 mM) and palmitate (0.4 mmol/L), 
compared to serum-free medium alone (Figure 2E and F). These effects were similar to those of Ex-
4. 
As assessed by Hoechst staining of apoptotic nuclei (Figure 2G) and caspase 3 activation (Figure 
2H), apoptosis was increased in cells cultured in serum free medium, compared to those in serum, 
and even more with cytokines or high glucose/palmitate. Both 43RFa and 26RFa, at 100 nmol/L 
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and similarly to Ex-4 (100 nmol/L), strongly reduced apoptosis in all experimental conditions 
(Figure 2G and H).  
Overall, these results indicate that 43RFa and 26RFa protect pancreatic β-cells against different 
diabetogenic stimuli. 
 
43RFa and 26RFa both promote survival and inhibit apoptosis in human pancreatic islets  
Similarly to INS1-E  β-cells, 43RFa and 26RFa increased survival and inhibited apoptosis in human 
pancreatic islets cultured for 72 h under either serum starvation, cytokine synergism or high 
glucose/palmitate. The peptides and Ex-4, that was used as positive control, were tested at 1, 10, 25, 
50 and 100 nmol/L in islets cultured in either serum-free medium alone or with IFN-γ/TNF-α/IL-1β. 
Under serum starvation, 43RFa and 26RFa increased survival at 100 nmol/L, having no significant 
effect at lower concentrations (Figure 3A). In the presence of cytokines, they both increased cell 
survival from 25 to 100 nmol/L, which was the best concentration tested (Figure 3B). Conversely, 
Ex-4 was effective at all concentrations in both experimental conditions and in a dose-dependent 
manner (Figure 3A and B). At 100 nmol/L, 43RFa- and 26RFa-induced survival was similar to that 
of Ex-4 and a dose-response was observed under cytokine treatment (Figure 3B). 100 nmol/L was 
also used in islets cultured in high glucose/palmitate, where the peptides equally increased islet cell 
survival (Figure 3C). Apoptosis, assessed by Hoechst staining and caspase-3 activity was inhibited 
by both 43RFa and 26RFa, in all experimental settings and similarly to Ex-4 (Figure 3D and E). 
These results indicate that, as for β-cells, in human islets 43RFa and 26RFa exert protective effects 
against different detrimental diabetogenic stimuli. 
 
43RFa survival effects involve activation of phosphoinositide 3-kinase (PI3K)/Akt and 
extracellular signal-regulated kinases (ERK)1/2, whereas only ERK1/2 is required for 26RFa-
induced cell survival  
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We next investigated the signaling pathways involved in the survival effects of the peptides, and 
specifically, PI3K/Akt and ERK1/2, whose activation plays a key role in β-cell growth and survival 
(28-30).  
In INS-1E cells, 43RFa increased the phosphorylation of both Akt  (at 15 min) and ERK1/2 (5 to 30 
min, compared to basal time point) (Figure 4A and B). 26RFa displayed no effect on Akt, at any 
time point (Figure 4C), whereas it promoted ERK1/2 increase, from 5 to 60 min compared to basal 
(Figure 4D). Similar effects were observed in human pancreatic islets, where 43RFa induced Akt 
and ERK1/2 phosphorylation (both at 5 to 30 min) (Figure 4G and H), whereas 26RFa promoted 
ERK1/2 (5 and 15 min) (Figure 4J), but not Akt activation (Figure 4I). Accordingly, in both INS-1E 
and human islets cultured in serum-free medium (Figure 4E and K) or in the presence of cytokines 
(Figure 4F and L), preincubation with the inhibitors for either Akt (wortmannin) or ERK1/2 
(PD98059) blocked the survival action of 43RFa, whereas that of 26RF was reduced only by 
PD98059 and not by wortmannin. These results suggest that both PI3K/Akt and ERK1/2 are 
involved in the survival effects of 43RFa, whereas for 26RFa, only ERK1/2 is engaged. 
 
43RFa promotes glucose-stimulated insulin secretion and potentiates Ex-4 insulinotropic 
action in β-cells and human islets, whereas 26RFa inhibits insulin release and reduces Ex-4 
effects  
We next sought to determine 43RFa and 26RFa effects on glucose-stimulated insulin secretion 
(GSIS) in both INS-1E and human pancreatic islets. The peptides were tested at different glucose 
concentrations, either alone or in combination with Ex-4, that was used as positive control. As 
expected, Ex-4 increased GSIS at all glucose concentrations, in both β-cells and islets. Similarly, 
43RFa increased insulin release at all glucose concentrations in β-cells and islets, to an extent 
comparable to that of Ex-4. 43RFa even increased basal insulin levels, without glucose stimulation. 
Moreover, Ex-4- and 43RFa-induced insulin secretion was further potentiated when Ex-4 and 
43RFa were given together, at 15 and 25 mmol/L glucose in INS-1E cells, and at 7.5, 15 and 25 
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mmol/L glucose in human islets (Figure 5A and B). On the other hand, 26RFa strongly inhibited 
both basal and GSIS, and dramatically reduced Ex-4 insulinotropic effects at all glucose 
concentrations, in either INS-1E β-cells or human islets (Figure 5A and B). 
To investigate the signaling pathways involved in the insulinotropic and insulinostatic effects of 
43RFa and 26RFa, respectively, INS-1E β-cells and human islet cells were preincubated with either 
pertussis toxin (PTX), an inhibitor of Gαi/o coupled receptor (31), or with NF449, a selective Gαs 
protein-coupled receptor antagonist (32). 43RFa-induced increase of insulin secretion was 
unaffected by pretreatment with PTX, whereas it was blocked by NF449, in both β-cells and islets. 
Conversely, PTX restored up to control levels GSIS, that was inhibited by 26RFa, whereas NF499 
had no effect on the insulinostatic action of the peptide (Figure 5C-F). These results suggest that the 
opposite effects of 43RFa and 26RFa on insulin secretion involve signaling through Gαs and Gαi/o, 
respectively. Furthermore, the role of GPR103 in 43RFa and 26RFa effects on GSIS was 
determined by transfecting INS-1E β-cells with small interfering RNA (siRNA) targeted to 
GPR103. As assessed by RT-PCR, at 24 after transfection GPR103 mRNA expression was strongly 
reduced by siGPR103, compared with scrambled (control) siRNA (Figure 5G). The insulinotropic 
effect of 43RFa, assessed at both 0 and 7.5 mmol/L glucose, was completely blocked in siGPR103 
cells, as compared to siControl, whereas 26RFa-induced inhibition of GSIS was unchanged in 
siGPR103 transfected cells (Figure 5H). These findings suggest that 43RFa promotes insulin 
secretion through binding to GPR103, whereas 26RFa inhibits insulin release likely through a 
different receptor. 
 
43RFa, but not 26RFa, promotes cAMP increase and glucose uptake in β-cells and human 
pancreatic islets 
cAMP elevation is linked to increased insulin secretion in pancreatic β-cells and protection from 
apoptosis (33,34). Therefore, we investigated the effects of 43RFa and 26RFa on cAMP levels in 
both INS-1E β-cells and human pancreatic islets. In INS-1E β-cells, 43RFa elevated intracellular 
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cAMP at 5 to 30 min with respect to basal (time 0), but not at 60 min, where cAMP returned to 
basal levels (Figure 6A). Conversely, 26RFa reduced cAMP levels, at the same time points (Figure 
6B). Similarly, in human pancreatic islets, cAMP was increased by 43RFa at 15 and 30 min and 
inhibited by 26RFa, at 5 to 30 min (Figure 6C and D). The cAMP-increasing agent forskolin was 
used as positive control. 
Glucose uptake by pancreatic β-cells, through the glucose transporter GLUT2 and glucokinase 
activity, is essential for the normal insulin secretory response to hyperglycemia (35,36). To further 
ascertain the stimulatory and inhibitory roles of 43RFa and 26RFa, respectively, on GSIS, glucose 
uptake was determined in INS-1E β-cells and human pancreatic islets. In INS-1E β-cells, at 10 min 
incubation 43RFa increased glucose 2-[
3
H]-deoxyglucose uptake at 10 nmol/L and showed a 
remarkable effect at 100 nmol/L, similarly to Ex-4 and to the cAMP analog 8-Br-cAMP. At 5 min, 
43RFa had no effect at 10 nmol/L, but stimulated glucose uptake at 100 nmol/L. Conversely, 26RFa 
had no effect, at any concentration and incubation time tested (Figure 6E). Similarly, in human 
pancreatic islets, that were tested for 10 min with 100 nmol/L of each peptide, 43RFa, but not 
26RFa, increased 2-deoxyglucose uptake (Figure 6F).  
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Discussion 
The present study shows that the RFamide peptides 43RFa and 26RFa both display survival and 
antiapoptotic effects in pancreatic β-cells and human pancreatic islets. Furthermore, 43RFa 
stimulated, whereas 26RFa inhibited the insulin response to glucose and Ex-4, in both β-cells and 
human pancreatic islets. These effects involved activation of distinct G proteins and different 
regulation of cAMP levels and glucose uptake.  
In mammals, the mRNAs encoding for the 43RFa and 26RFa precursor (QRFP) and for its receptor 
GPR103, are mainly expressed in the brain, particularly in the hypothalamus, and in different 
peripheral organs (6,9). QRFP mRNA has been found expressed in mouse and rat pancreas, but not 
in human pancreas (37). GPR103 was reported to be absent in human pancreas and expressed at 
very low level in mouse pancreas (6,7,37). Here we show QRFP and GPR103 expression in both rat 
INS-1E β-cells and human pancreatic islets, either at mRNA or protein level. Interestingly, in 
human islets, GPR103 protein co-localized with insulin, suggesting direct interaction of 43RFa and 
26RFa with their receptor in β-cells. Furthermore, QRFP expression in β-cells and human islets 
may suggest autocrine/paracrine effects of the peptides. Accordingly, 26RFa autocrine/paracrine 
effects have been recently proposed in prostate cancer cells, where the peptide induced cell 
migration and neuroendocrine differentiation, and in macrophages and adipocytes, where both 
43RFa and 26RFa promoted adipogenesis (10,11,22). Future studies will help elucidate whether 
autocrine/paracrine mechanisms may also occur in pancreatic islets. 
We firstly report here the survival and antiapoptotic effects of 43RFa and 26RFa. Pancreatic β-cells 
and human pancreatic islets were chosen as in vitro models because, besides the survival actions, 
we were interested in the metabolic effects of these peptides. Indeed, a role in adipogenesis, lipid 
metabolism and inflammation, as well as an association between GPR103 and QRFP expression 
and obesity, have been recently described (10,11). Moreover, as for QRFP, other orexigenic 
peptides such as ghrelin, exert antiapoptotic and metabolic effects in different cell types, including 
pancreatic β-cells and human islets (24,38,39). Here, both 43RFa and 26RFa increased survival and 
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inhibited apoptosis of INS-1E β-cells and human pancreatic islets. They also increased proliferation 
of INS-1E β-cells, that was not investigated in human islets, due to the low proliferative rate of 
human β-cells in vitro (40,41). Besides serum starvation, which induces β-cell death (24,42), β-cells 
and human islets were challenged with diabetogenic stimuli, such as cytokine synergism and 
glucolipotoxicity, which are major causes of β-cell dysfunction and death in both type 1 and 2 
diabetes (1-4). Interestingly, 43RFa and 26RFa both displayed proliferative, survival and 
antiapoptotic actions, comparable to those of the long acting GLP-1 agonist Ex-4 (27).  
Phosphorylation of either PI3K/Akt or ERK1/2 has been shown to mediate β-cell proliferation and 
survival in response to different external signals, including incretin hormones (24,27,30,43). Here, 
43RFa and 26RFa, although displaying similar survival effect in β-cells and human islets, 
differently regulated these signaling pathways. In fact, whereas 43RFa increased the 
phosphorylation of both PI3K/Akt and ERK1/2, 26RFa increased ERK1/2, but not PI3K/Akt. 
Accordingly, inhibition of PI3K and ERK1/2 phosphorylation with wortmannin and PD98059, 
respectively, blocked 43RFa-induced survival, whereas only ERK1/2 inhibitor decreased 26RFa-
induced survival. These results indicate that ERK1/2, and not PI3K/Akt, is required for 26RFa 
survival effect, whereas 43RFa uses both pathways. Notably, a cross talk between ERK1/2 and 
cAMP in pancreatic β-cell survival has been previously described (29). However, here only 43RFa 
elevated cAMP levels, suggesting that 26RFa-induced activation of ERK1/2 is independent of the 
cAMP pathway. 
To further understand the effects of 43RF and 26RFa in β-cells we next determined their role on 
insulin secretion. To our knowledge, 43RFa effect on insulin secretion has never been studied. 
Instead, 26RFa was recently shown to inhibit glucose- as well as arginine- and Ex-4-induced insulin 
secretion in perfused rat pancreas (23). Here, we firstly show that 43RFa promoted insulin secretion 
in INS-1E β-cells and human islets, both in basal conditions and in the presence of either different 
glucose concentrations or Ex-4. Conversely, 26RFa showed opposite effects and inhibited both 
glucose- and Ex-4-induced insulin secretion, in agreement with the previous findings (23). 26RFa 
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was used here at 100 nmol/L, which was also the best concentration to promote survival and 
prevent apoptosis. Conversely, 10 nmol/L was the concentration used in the study by Egido et al., 
where the experiments were performed in perfused rat pancreas, at variance with our in vitro 
models (23).  
Interestingly, either 43RFa or Ex-4 alone, showed comparable insulinotropic action in both β-cells 
and human islets. Moreover, insulin secretion was markedly increased when 43RFa and Ex-4 were 
administered together, particularly at the highest concentrations of glucose. On the other hand, 
besides exerting inhibitory action per se, 26RFa hampered Ex-4 insulinotropic effect. These results 
imply that 43RFa may either potentiate Ex-4 action or act synergistically with Ex-4 to increase 
insulin secretion, whereas 26RFa behaves in an opposite manner. They also suggest clinical 
implications in diabetes, as 43RFa may become a therapeutic target for enhancing β-cell function, 
alone or in combination with incretin hormones, whereas inhibition of 26RFa effect may prevent 
loss of β-cell competence. 
Activation of G protein-coupled receptors (GPCRs) by metabolites and hormones can modulate 
glucose-induced insulin secretion through different pathways. Gαs-coupled receptors increase 
insulin secretion through stimulation of adenylyl cyclase and activation of protein kinase A (PKA) 
by cAMP. In turn, Gαi/o-coupled receptors reduce insulin release by inhibition of adenylyl cyclase 
and cAMP formation and also through inhibition of voltage-dependent Ca
2+
 channels involving the 
βγ subunits of Gαi/o (27,44). We found here that the Gαs antagonist NF449 blocked the 
insulinotropic effect of 43RFa, but not the insulinostatic action of 26RFa. Conversely, the Gαi/o 
inhibitor PTX did not affect 43RFa-induced insulin release, but blocked the inhibitory effect of 
26RFa, in both β-cells and human islets. This in agreement with the findings by Egido et al. (23), 
except for the fact that here PTX was used in combination with glucose only, and not with Ex-4.  
Of note, PTX alone had no effect here on GSIS, whereas with 26RFa, insulin levels were found 
increased. This is likely because glucose alone, in the absence of GPCR ligands, causes inhibition 
of ATP-regulated K
+
 channels, opening of voltage-dependent Ca
2+
 channels and increase in 
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intracellular Ca
2+
 concentration ([Ca
2+
]i), which triggers exocytosis of insulin-containing vesicles 
(45). Conversely, in the presence of 26RFa, PTX may restore cAMP levels, which are blunted by 
the peptide, as well as ([Ca
2+
]i), and may thus contribute to increase insulin release.  
Our results indicate that the opposite effects of 43RFa and 26RFa on insulin secretion are due to 
activation of distinct pathways. In fact, 43RFa promotes insulin secretion, at least in part, through 
Gαs and adenylyl cyclase/cAMP increase, whereas 26RFa inhibits insulin release through Gαi/o and 
inhibition of cAMP formation. This assumption is further sustained by our results showing that 
43RFa increased, whereas 26RFa inhibited intracellular cAMP levels in both INS-1E β-cells and 
human pancreatic islets. At variance with these findings, 43RFa has been recently found to decrease 
forskolin-induced cAMP in human adrenocortical cells, likely through Gq-mediated mechanisms 
(20). 26RFa, instead, in line with our results, was shown to decrease cAMP production in Chinese 
hamster ovary (CHO)- or human embryonic kidney (HEK293)-GPR103 transfected cells, 
suggesting GPR103 coupling to Gi/o and Gq (7). In addition, we found here that similarly to the 
cAMP analog 8-Br-cAMP and to Ex-4, 43RFa, but not 26RFa, increased glucose uptake, which is 
required in the initial step of GSIS by pancreatic β-cells and has been shown to be impaired in both 
type 1 and type 2 diabetes (35,46). Collectively, these findings further support the positive role of 
43RFa on β-cell function, which is opposed to that of 26RFa.  
An open question during the study was why two peptides, that likely bind the same receptor, exert 
opposite effects on insulin secretion. To solve this issue, we knocked down GPR103 expression in 
INS-1E β-cells using specific siRNA, and found complete inhibition of 43RFa insulinotropic action, 
but no effect on 26RFa-induced insulin inhibition. This finding suggests that in β-cells, only 43RFa 
signals through GPR103, whereas 26RFa interacts with a different receptor. Accordingly, 26RFa 
was found to display moderate affinity and selectivity for NPFF2, the receptor of neuropeptide FF, 
another member of the RFamide family (47). Moreover, NPFF and prolactin-releasing peptide 
(PrRP), both with high affinity for NPFF2 receptor (9), displaced [
125
I]-26RFa binding in brain 
regions enriched with NPFF2 receptor (48). Interestingly, NPFF2 receptor is coupled to Gi/o protein, 
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in agreement with our finding showing loss of 26RFa insulinostatic effect in β-cells and human 
islets treated with PTX.  
In conclusion, this study shows a new role for 43RFa and 26RFa in promoting β-cell and human 
islet cell survival, while exerting opposite effects on insulin secretion, via either Gαs/cAMP 
elevation or Gi/o/cAMP inhibition, respectively. The effects on insulin secretion require GPR103 
binding for 43RFa, but not for 26RFa. These findings provide new perspectives and comprehension 
on the role of these peptides, whose functions, particularly at the peripheral level, are still quite 
unknown. In addition, 43RFa and 26RFa may become novel therapeutic targets for increasing β-cell 
mass and function in metabolic diseases such as diabetes and obesity.  
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Figure legends 
Figure 1. Gene and protein expression of GPR103 and QRFP (the RF43a and 26RFa precursor) in 
INS1-E β-cells and human pancreatic islets (H. islets). (A, B) GPR103 (A) and QRFP (B) mRNA 
assessed by RT-PCR. Rat brain (A and B) and adult hippocampal progenitor cells (AHPs) (A) were 
used as positive control; 18s rRNA was used as internal control. (C and D) GPR103 (C) and QRFP 
(D) protein expression assessed by Western blot on whole lysates from INS-1E β-cells or human 
pancreatic islets. Equal protein loading was determined by reprobing with antibodies to β-actin. The 
blots are representative of three independent experiments. (E) Immunofluorescent staining of 
GPR103 in INS-1E β-cells. GPR103 is shown in red and nuclei in blue (DAPI); AHPs were used as 
positive control. Each image is representative of three independent experiments (X40). (F) GPR103 
expression in human pancreatic islets assessed by immunofluorescent staining. Insulin is shown in 
green and GPR103 in red (X40) (n=3). Merge shows colocalization of GPR103 and insulin 
(yellow), as indicated by arrows. (G) Immunohistochemical analysis of GPR103 and QRFP 
expression in INS-1E β-cells. Cells incubated without the primary antibody were used as negative 
control (-). (H) Immunohistochemical analysis of GPR103 and QRFP expression in human 
pancreas; pituitary was used as positive control (n=3). 
 
Figure 2. 43RFa and 26RFa effects on survival, proliferation and apoptosis of INS-1E β-cells. The 
cells were cultured in serum-free medium (SF) for 12 h, then incubated for a further 24 h without or 
with the cytokines (CK) TNF-α/IFN-γ/IL-1β (100, 50 and 5 ng/ml respectively), or with high 
glucose (30 mmol/L) and palmitate (0.4 mmol/L) (P/G), and either with 43RFa, 26RFa or Ex-4. The 
peptides were added 40 min prior to CK or P/G. (A-D) Cell survival and proliferation (assessed by 
MTT and BrdU, respectively) in the absence (A, C) or presence (B, D) of CK and the peptides, at 
the indicated concentrations. Data are expressed as percent of control (SF) and are the mean ± SE of 
five replicates (n=3) (*P<0.05, **P <0.01 vs. SF; 
#
P<0.05, 
##
P<0.01 vs. CK; ns, not significant). 
Cell survival (E) and cell proliferation (F) in cells cultured in SF medium, alone or with P/G and the 
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indicated peptides (100 nmol/L each). Results are expressed as percent of control (SF); n=3. 
(**P<0.01 vs. SF; 
#
P<0.05, 
##
P<0.01 vs. P/G). (G) Apoptosis assessed by counting 
condensed/fragmented Hoechst stained apoptotic nuclei. Values are expressed as percent of 
apoptotic cells and are the mean ± SE of duplicate determinations (500 cells each) from three 
independent experiments. (H) Apoptosis assessed as caspase-3 activation and expressed as percent 
of control (SF). (For both G and H: **P<0.01; 
##
P<0.01 vs. SF; n=3). Each peptide was used at 100 
nmol/L. 
 
Figure 3. 43RFa and 26RFa effects on survival and apoptosis of human pancreatic islets. Islet cells 
were incubated for 72 h in the presence of serum or in serum-free medium (SF), either alone or with 
IFN-γ/TNF-α/IL-1β (CK) (5 ng/ml each) and 43RFa or 26RFa. (A, B) Cell viability assessed by 
MTT in islets cultured in serum-free medium  (SF), alone (A) or with cytokines (CK) (B) and the 
peptides at the indicated concentrations. Results are expressed as percent of control (SF, n=3) 
(*P<0.05, **P<0.01 vs. SF for A or vs. CK for B; ns, not significant). (C) Cell survival (MTT) in 
human islets treated in SF medium alone or with high glucose (30 mmol/L)/palmitate (G/P) (0.4 
mmol/L) and the indicated peptides (100 nmol/L each). Results are expressed as percent of control 
(SF); n=3. (*P<0.05, **P<0.01 vs. SF; 
##
P<0.01 vs. P/G). (D) Apoptosis assessed by Hoechst 
staining. Values are expressed as percent of apoptotic cells from duplicate determinations (500 cells 
each, n=3). (E) Apoptosis assessed by caspase-3 activation. Results are expressed as percent of 
control (SF). (For both D and E: *P<0.05, **P<0.01; 
##
P<0.01 vs. SF; n=3). Each peptide was used 
at 100 nmol/L. 
 
Figure 4. 43RFa and 26RFa effects on activation of PI3K/Akt and ERK1/2. Akt and ERK1/2 
phosphorylation was assessed by Western blot on whole lysates from INS-1E cells or human 
pancreatic islets stimulated with either 100 nmol/L 43RFa (A-B and G-H) or 100 nmol/L 26RFa (C-
D and I-J), for the indicated times (top panels). Equal protein loading was determined by reprobing 
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with antibodies to the respective total proteins (bottom panels). Blots are representative of three 
independent experiments. Graphs show the densitometric analysis of phosphorylated proteins 
normalized to total proteins and reported as percent of basal (*P<0.05, **P<0.01; ns, not 
significant). (E and F) Cell survival assessed by MTT in INS-1E cells that were starved for 12 h, 
then incubated for a further 24 h in the absence or presence of either 43RFa (43) or 26RFa (26) (100 
nmol/L each), and either without (serum-free medium, SF) (E) or with TNF-α/IFN-γ/IL-1β 
(cytokines, CK) (100, 50 and 5 ng/ml respectively) (F), and wortmannin (WM) (100 nmol/L) or 
PD98059 (40 µmol/L). Inhibitors were added 30 and 60 min before the peptides and cytokines, 
respectively. **P<0.01 vs. SF (E) or vs. CK (F); 
##
P<0.01 vs. 43; 
§
P<0.05 vs. 26; ns, not 
significant; n=3. (K and L) Cell survival assessed by MTT in human pancreatic islets incubated for 
72 h in the presence of serum or in serum-free medium (SF), either alone (K) or with IFN-γ/TNF-
α/IL-1β (CK) (5 ng/ml each) and 43RFa or 26RFa (100 nmol/L each). Inhibitors were added as for 
E and F. **P<0.01 vs. SF (K) or vs. CK (L); 
#
P<0.05, 
##
P<0.01 vs. 43; 
§
P<0.05 
§§
P<0.01 vs. 26; ns, 
not significant; n=3. 
 
Figure 5. 43RFa and 26RFa regulate insulin secretion in INS-1E β-cells and human pancreatic 
islets. Insulin release was assessed by RIA in conditioned medium from INS-1E β-cells or islets, 
incubated alone or with 2 mmol/L glucose for 1 h and then for a further 1 h with the indicated 
concentrations of glucose, in the presence or absence of either 43RFa, 26RFa, Ex-4 or a 
combination of Ex-4/43RFa or Ex-4/26RFa (100 nmol/L each). (A) Insulin secretion in INS-1E β-
cells. (B) Insulin secretion in human pancreatic islets. For A and B, values are the means ± SE of 
triplicate determinations from at least three independent experiments (*P<0.05, **P<0.01 vs. 
Control at each glucose concentration; 
#
P<0.05, 
##
P<0.01). (C-F) Insulin secretion in INS-1E cells 
(C and D) and human pancreatic islets (E and F) in either absence or presence of pertussis toxin 
(PTX) (50 ng/ml) or NF449 (10 µmol/L). *P<0.05, **P<0.01 vs. control (c) at each glucose 
concentration; 
#
P<0.05, 
##
P<0.01; ns, not significant. (G) GPR103 mRNA assessed by RT-PCR in 
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INS-1E β-cells after 24 h transfection with either nonsilencing siRNA (siControl) or siRNA to 
GPR103 (siGPR103). As expected, the amplified products corresponded to 318 bp for rat GPR103, 
and 199 bp for 18s rRNA, that was used as internal control. (H) Insulin secretion in siControl- or 
siGPR103-transfected INS-1E β-cells, incubated for 1 h with the indicated concentrations of 
glucose, and with 43RFa or 26RFa (100 nmol/L each). Values are the means ± SE of triplicate 
determinations from at least three independent experiments (*P<0.05 vs. Control at each glucose 
concentration; 
#
P<0.05). 
 
Figure 6. 43RFa and 26RFa effects on intracellular cAMP and glucose uptake. (A-D) Serum-
starved INS-1E cells and human islets were cultured for the indicated times with either 100 nmol/L 
43RFa or 100 nmol/L 26RFa, in the presence of the phosphodiesterase inhibitor IBMX (100 
µmol/L), that was added 30 min before stimulation. Forskolin (Forsk) (50 µmol/L for 1 min) was 
used as positive control. Results are the mean  ±SE of three independent experiments performed in 
triplicate (*P<0.05, **P<0.005 vs. basal time point; ns, not significant). (E) 2-[3H]-deoxyglucose 
glucose uptake assessed in serum starved INS-1E cells cultured for 5 or 10 min with either Ex-4, 
43RFa or 26RFa, at the indicated concentrations. (F) 2-[3H]-deoxyglucose glucose in human 
pancreatic islets cultured for 10 min with the peptides, that were used at 100 nmol/L each. 8-Br-
cAMP was used at 1 mmol/L. For E and F: n=3; *P<0.05**P<0.005, ***P<0.001; ns, not 
significant vs. control. 
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